After the GLP-1 shortage era: what compounders and telehealth desks are watching

When branded GLP-1 injectables moved off FDA's shortage list, the operational question for many telehealth and pharmacy teams stopped being "can we compound through shortage?" and became "what documentation and volume limits still hold under 503A and 503B?"

FDA keeps a rolling set of updates on a single statement page: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. That page includes dated entries on shortage resolutions, temporary enforcement-discretion windows, litigation-related timeline notes, and an April 1, 2026 reminder of conditions for exemptions under sections 503A and 503B of the FD&C Act.

According to FDA's April 1, 2026 update, under section 503A the drug product is to be compounded for an individual patient based on a prescription, and the compounder must not compound regularly or in inordinate amounts any drug products that are essentially copies of a commercially available drug product.

FDA states that, as described in guidance, it intends to consider a compounded product essentially a copy if it has the same active pharmaceutical ingredient(s) in the same, similar, or easily substitutable strength, and the commercially available product can be used by the same route of administration prescribed for the compounded product. An exception applies when a prescriber determines and documents that the compounded product contains a change that produces a significant difference for an identified individual patient.

The same update describes how FDA may view certain combination products. For example, FDA says it may consider a compounded product that combines semaglutide API with another API such as vitamin B12 to be essentially a copy when route of administration matches and strengths fall within the agency's described similarity window. FDA also states that, at this time, it does not intend to take action against a compounder for compounding a drug that is essentially a copy regularly or in inordinate amounts if the compounder fills four or fewer prescriptions of that compounded product during a calendar month.

Under section 503B, the April 2026 update restates that outsourcing facilities are restricted from compounding from bulk drug substances unless the bulk appears on the 503B bulks list or the compounded drug is on FDA's shortage list at compounding, distribution, and dispensing. The update notes that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list.

The same FDA page archives earlier determinations, including FDA's February 21, 2025 update that the shortage of semaglutide injection products was resolved, and December 19, 2024 language determining the tirzepatide injection shortage was resolved, plus described enforcement-discretion windows and later notes tying some end dates to court decisions in Outsourcing Facilities Association v. FDA matters in the Northern District of Texas. Operators say they treat those dated entries as a chronology to reconcile with counsel, not as a substitute for the current shortage database.

FDA's page continues to stress that compounded drugs are not FDA-approved and that the agency may still act on other statutory or regulatory requirements, including quality or safety concerns.

This is not legal advice. Teams watching the beat typically track three process questions: shortage status in FDA's Drug Shortages Database today; whether 503A records document a patient-specific significant difference when that is the theory of the case; and whether any 503B volume still depends on bulks-list or shortage-list conditions that no longer apply to tirzepatide or semaglutide per FDA's stated update. State boards may publish stricter FAQs; operators say they watch those in parallel, especially for multi-state telehealth prescribing.

Primary source: FDA compounder GLP-1 policy statement.